Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer

Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.

The use of CDK inhibitors (palbociclib, ribociclib, abemaciclib) for patients with metastatic ER-positive breast cancer has been shown to prolong time to disease progression. Currently, several large randomized clinical trials have been initiated to assess the role of CDK inhibitors in the adjuvant setting for patients with early-stage ER-positive disease, but the results of these trials won't be known for several years.

Using the preoperative setting as an opportunity to assess the biologic and clinical effect of CDK inhibition in operable ER-positive breast cancer, investigators have conducted a single-arm, phase II neoadjuvant trial (NeoPalAna) involving 50 patients with clinical stage II/III, ER-positive, HER2-negative disease. All were …

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)